An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recombinant Adeno-associated Virus Vector (AAV5 hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
Latest Information Update: 22 Oct 2024
At a glance
- Drugs Botaretigene sparoparvovec (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 22 Oct 2024 New trial record